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Abstract Parkinson’s disease (PD) is a progressive neurolog-
ical disorder characterized primarily by the degeneration of
nigrostriatal dopaminergic neurons and diminution of the
neurotransmitter dopamine. Though dopamine replacement
therapies such as levodopa can improve the symptoms of
PD, the benefits may be overshadowed by side effects and
the onset of symptoms not responsive to dopaminergic treat-
ments (e.g., autonomic symptoms, gait and balance problems,
and cognitive impairment). Furthermore, no therapies have
proven to slow the neurodegenerative process. Novel ap-
proaches to address these difficult problems, and others, are
being sought. Over the last decade, several innovative gene
therapies for PD have entered human clinical trials in an effort
to address both symptomatic and potential disease-modifying
effects. Though the results of these trials have been mixed, the
therapies have generally been safe and well-tolerated, suggest-
ing gene therapy may be a viable treatment for PD in the
future. This article will review past and current clinical trials
of gene therapies for PD. In addition, novel preclinical ap-
proaches to gene therapy for PD will be described.
Keywords Parkinson’s disease . Gene therapy . Clinical
trials . Neurodegeneration . Dopamine
Introduction
Gene therapy involves the use of a gene (or, more broadly,
genetic material, including DNA and RNA) as an agent to
alter cellular/biological function and treat disease. Though
traditionally gene therapy has been primarily thought of as a
means for correcting a genetic defect, many other gene-based
therapeutic strategies for disorders that are not primarily ge-
netic in origin [such as Parkinson’s disease (PD)] have been
conceived and tested. These approaches may be particularly
advantageous in neurological diseases, as they provide a
means for targeting specific molecular pathways and brain
regions [1].
Clinical gene therapy can be classified into 1 of 2 catego-
ries: 1) ex vivo gene therapy, in which cells are genetically
modified in culture to express a desired protein or proteins and
then transplanted into the patient; and 2) in vivo gene therapy,
in which genetic information is directly inserted into the
patient’s own cells. Though ex vivo gene therapy strategies
may have a role in the treatment of PD [2–4], to date, all
human clinical trials of gene therapies for PD have been
conducted with the in vivo method, utilizing viral vectors to
introduce specific genes into the patient’s own neurons.
Gene therapy, however, carries specific risks that need to be
considered before conducting human clinical trials. One risk is
the uncontrolled overproduction of the targeted protein
resulting in adverse effects. Gene promoter regions could,
theoretically, be used to control gene expression [5], but these
approaches have not been tested in human clinical trials.
Another potential risk of in vivo gene therapy is insertional
mutagenesis, in which the introduced gene inserts into the host
genome at a site promoting oncogenesis causing neoplastic
transformation of the host cell [6]. This risk can be mitigated
by the use of viral vectors known to have a relatively low risk
of causing this phenomenon [7], but, nonetheless, it remains a
concern. Finally, gene therapy may induce an autoimmune
and inflammatory response. For example, a gene therapy trial
utilizing an adenoviral vector for the treatment of ornithine
transcarbamylase deficiency resulted in a fatal inflammatory
response in one patient [8]. Though this risk can also be
mitigated by the use of certain viral vectors, monitoring for
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immune and inflammatory responses during gene therapy
clinical trials is commonly undertaken.
Gene Delivery Vectors
Advances in the understanding and construction of viral and
nonviral vectors for gene transfer have enabled gene therapy
to become a realistic form of treatment for many neurological
diseases, including PD. The 2 most commonly used viral
vectors are lentivirus and adeno-associated virus (AAV).
Historically, herpes simplex virus and adenovirus have also
proven to be useful, but concerns of resulting inflammatory
responses and toxicity have since led to their abandonment
[1]. Removal of the genes responsible for virus replication has
lowered the risk of secondary immune reactions with the AAV
vector, particularly when used in the brain [9–11]. Because the
vector is essentially devoid of the viral genome, the large
majority of viral DNA remains episomic and is not incorpo-
rated into the host genome, thereby additionally reducing the
risk of insertional mutagenesis. Though the size of the AAV
vector restricts the gene constructs that it can deliver, the
aforementioned advantages have led to its near-dominance
in human clinical gene therapy trials, particularly in PD.
Larger gene constructs can be accommodated by a lentivirus
for transduction in dividing and nondividing cells. Generated
from a pathogenic retrovirus, the lentiviral vector integrates
into the host genome and may produce longer-term transgene
expression. Importantly, targeted neurons of the lentiviral
vector are typically postmitotic, which may limit the risk of
insertional mutagenesis. Regardless of the vector used, how-
ever, a major problem in gene therapy for neurological disor-
ders is delivering the gene across the blood–brain barrier
(BBB); neither lentivirus nor AAV vectors can cross the
BBB, so all human gene therapy clinical trials in PD to date
have involved the direct infusion of the viral vector into
specific targets in the brain via a craniotomy.
Several nonviral methods of gene delivery are being inves-
tigated in preclinical models. For example, it may be possible to
transfer genetic material efficiently utilizing a gene gun or
electroporation [12]. The former achieves direct gene delivery
into tissues or cells by injecting gold particles coated with
DNA, which can permeate into the nucleus of the cell [13].
Similarly, electroporation utilizes a method for enhancing cell
permeability to improve gene delivery by applying controlled
electric fields after the genetic material has been injected [13].
An alternative to direct injection is administering genetic ma-
terial intranasally, which may allow access to the central ner-
vous system (CNS) and bypass the technical problem of getting
gene therapy across the BBB [14, 15]. Genetic information can
also be transferred via liposomes which, once coated with
polyethyleneglycol (PEG), are stable in blood and can be
further modified for active transport into the CNS [16, 17].
These PEGylated immunoliposomes may provide additional
utility in that they can remain episomal and thus reduce the risk
of insertional mutagenesis, though the degradation of exoge-
nous genetic material may require repeat treatments [18].
PD Gene Therapy Clinical Trials
Five PD gene therapies have been tested in early phase human
clinical trials (see Table 1), and all of them have utilized the
AAV or lentivirus vectors for gene transfer; these trials have
included therapies aimed at both symptomatic and disease-
modifying effects. The symptomatic approaches have focused
on either increasing dopamine production by transducing
genes involved in neurotransmitter synthesis or normalizing
basal ganglia circuitry by altering the neuronal phenotype
[19]. With regard to disease modification, several trials have
been conducted utilizing a gene for a neurotrophic factor
(Neurturin) in an attempt to increase dopaminergic nerve
terminals.
AAV-Glutamic Acid Decarboxylase
In PD, the loss of dopaminergic nigrostriatal neurons results in
downstream changes in basal ganglia circuitry, including de-
creased gamma-aminobutyric acid (GABA)ergic input into the
subthalamic nucleus (STN). GABAergic drugs infused into the
STN can improve symptoms in PD patients [20]. Over the last
10 years, 2 early phase clinical trials have investigated a gene
therapy approach for increasing GABAergic tone in the STN.
This treatment utilized an AAV vector for delivery of the gene
for glutamic acid decarboxylase (GAD), the rate-limiting en-
zyme for the synthesis of GABA, to the STN. The goal of this
therapy is to regulate STN firing rates thereby improving the
motor features of PD [12].
The first human trial of in vivo gene therapy for a neuro-
degenerative disorder evaluated the safety and tolerability of
AAV2–GAD gene therapy in a phase 1, open-label, dose-
escalation study in 12 moderately advanced PD patients
[21]. All patients had Hoehn and Yahr stage 3 or greater PD,
and were considered candidates for deep brain stimulation
surgery on the basis of having intolerable motor complications
of levodopa. Each patient received 1 of 3 AAV2–GAD doses,
which were injected unilaterally into the STN, contralateral to
the more clinically impaired side. During 12 months of
follow-up, no treatment-related adverse events and no im-
mune responses were observed. Improvements in total motor
Unified Parkinson’s Disease Rating Scale (UPDRS) scores
were seen in both the on and off states after 3 months and
persisted for the duration of the study. In addition, metabolic
imaging data acquired using [18F]fluoro-deoxyglucose posi-
tron emission tomography (PET) revealed a treatment-
mediated reduction in brain metabolism in the pallidum and
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the thalamus on the operated side [22]. Improvements in
motor UPDRS ratings were associated with increases in me-
tabolism in the premotor cortex of the operated hemispheres,
suggesting that STN gene therapy altered the activity of the
motor cortico-striato-pallido-thalamo-cortical circuit in a man-
ner that would be expected to improve motor function [23].
The highest AAV2–GAD dose (1×1012 vg/ml) was subse-
quently tested in a phase 2 randomized, double-blind, sham
surgery-controlled trial [24]. Forty-four patients with progres-
sive, levodopa-responsive PD were studied; 21 patients were
randomized into the AAV2–GAD group and 23 patients into
the sham group. Study treatment was infused bilaterally into
the STN for both groups; the sham group received infusion of
intradural sterile saline (no brain penetration) in place of
AAV2–GAD. No major adverse effects related to the opera-
tion or gene therapy treatment were reported by any patients
during the study. Over the course of the 6-month study, the
AAV2–GAD group demonstrated improvement in UPDRS
motor scores compared with the sham group (AAV2–GAD
23 % vs sham group 13 %). This treatment effect remained
significant at 12 months (unpublished data). Other clinical
measures also suggested improvement in the AAV2–GAD
group, including measures of consistency of medication effect
and freezing of gait. Importantly, the absence of significant
adverse events related to AAV2–GAD was also sustained
through 12 months of follow-up.
AAV–Aromatic L-Amino Acid Decarboxylase
Pharmacological treatment of PD with oral administration of
levodopa remains the gold standard symptomatic therapy for
PD. However, over time, the beneficial effects of levodopa
can be complicated by motor fluctuations and dyskinesias.
Continuous dopamine stimulation may counterbalance these
negative long-term effects of drug use [25], prompting the
investigation of gene therapy approaches to improve levodopa
metabolism.
One such symptomatic gene therapy approach for PD
focuses on improving dopamine replacement therapies by
enhancing the efficiency of levodopa conversion to dopamine.
Aromatic L-amino acid decarboxylase (AADC) is the enzyme
that converts endogenous or pharmacologically administered
levodopa to dopamine. In PD, however, AADC activity di-
minishes with the progressive loss of nigrostriatal neurons,
further limiting endogenous dopamine levels and leading to
the need for larger dosages of levodopa in advancing disease
[1]. Transduction of intrinsic striatal neurons with the AADC
gene can enhance dopamine synthesis and may improve the
efficacy of levodopa treatment. Moreover, if the dose of
levodopa needed to achieve therapeutic benefit can be de-
creased, this could lead to a reduction in associated side
effects.
An early phase human dose-ranging clinical trial assessing
the safety and efficacy of utilizing an AAV2 vector to trans-
duce striatal neurons with the AADC gene has been completed
[26, 27]. Ten patients received bilateral posterior putaminal
infusion of either low- or high-dose AAV2–AADC, in con-
junction with orally administered levodopa. No significant
adverse effects related to the viral vector were reported; how-
ever, 3 patients experienced intracranial hemorrhage from
surgery. Only 1 of these patients was symptomatic, but he
made an almost complete recovery. Improvements in total and
motor UPDRS scores were observed in both the on and off
states during 6 months of follow-up. PET imaging using the
AADC tracer [18F]fluoro-L -m-tyrosine revealed an increase
in striatal AADC activity at 6 months postinfusion, and these
Table 1 Gene therapy clinical trials in Parkinson’s disease
Gene Viral
vector
Target Study
phase
n Primary outcome
measure
Study
duration
Baseline H&Y
(UPDRS)
Baseline LD
therapya (LD eq.)
Ref.
GAD AAV2 STN 1 12 Safety 12 months ≤ 3 (39.2) 1083 (1402) [21, 22]
2 44 UPDRS 6 months 2.8 (37.2) 891.8 [24]
AADC AAV2 Putamen 1 10 Safety 6 months 3–4 (38.6) 771 (1050) [26, 27]
TH + GCH1 +
AADC (Prosavin)
Lenti-virus Striatum 1 15 Safety 12 months 3–4 (20–60) U/A [31]
2 15 UPDRS 6 months U/A U/A [32]
Neurturin
(CERE-120)
AAV2 Putamen 1 12 Safety 12 months 3.1 (42) (1783) [45]
2a 58 UPDRS 12 months 3.0 (38.8) 715.1 (1067.6) [46]
Neurturin
(CERE-120)
AAV2 SNc and
putamen
1 6 Safety 15–24 months 2.8 (38.2) U/A [47]
2b 51 UPDRS 15–24 months ≤ 3 U/A [48]
GDNF AAV2 Putamen 1 24 Safety 5 years 3–4 (≥ 30) U/A [49]
H&Y Hoehn andYahr;UPDRS Unified Parkinson’s Disease Rating Scale (off-state motor score); LD levodopa; LD eq. levodopa equivalent dose;GAD
glutamic acid decarboxylase; AADC aromatic L- amino acid decarboxylase; TH tyrosine hydroxylase;GCH1 guanosine triphosphate cyclohydrolase 1;
GDNF glial cell-derived neurotrophic factor; AAV adeno-associated virus; STN subthalamic nucleus; SNc substantia nigra pars compacta; U/A
unavailable
amg daily
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changes correlated with clinical improvements. The improve-
ment in both off and on state UPDRS scores suggests that
AADC gene therapy may enhance the conversion efficiency
for both endogenous and orally administered levodopa. The
effective dose of levodopa decreased for all patients in the
high-dose group and 3 patients in the low-dose group [27].
These promising results will need to be confirmed in a ran-
domized, double-blind clinical trial.
Tyrosine Hydroxylase/AADC/Guanosine Triphosphate
Cyclohydroxylase
A similar symptomatic therapy has been developed that aims
to increase striatal dopamine not only by restoring AADC
activity, but also by further increasing endogenous levodopa
in dopaminergic and nondopaminergic neurons [28–30].
This approach utilizes 3 genes involved in the production
of dopamine: AADC , tyrosine hydroxylase (TH ), and gua-
nosine triphosphate cyclohydrolase (GCH ). TH and GCH
catalyze the synthesis of levodopa from dietary tyrosine,
which can then be converted to dopamine via AADC. The
potential value of this treatment has been demonstrated in
6-hydroxydopamine (6-OHDA) rodent and1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP) primate PDmodels.
Utilizing triple intrastriatal transduction with 3 AAV vectors
separately encoding AADC, TH, and GCH, improvements in
dopamine concentrations were observed leading to the devel-
opment of a single lentivirus vector to transduce genes for all 3
enzymes. This triple gene approach [Lenti–TH–AADC–GCH
(ProSavin)] has been demonstrated to increase extracellular
striatal dopamine concentrations in animal models of PD
[24]. In addition, long-term expression of the dopamine-
modifying genes in the striatal neurons may be achiev-
able with this method as lentivirus-delivered genes inte-
grate into the host genome. The goal of this therapy is to
provide more continuous (less pulsatile) dopamine delivery
targeted to the motor portion of the striatum, perhaps reducing
the risk of levodopa-associated complications such as dyski-
nesias and hallucinations.
After successful demonstration in animal models [30],
ProSavin has advanced into early phase human clinical trials.
The initial open-label, dose-escalation study tested 3 doses in
15 moderate-to-advanced PD patients [31]. All patients had
Hoehn and Yahr stage 3 or greater PD, and were considered
candidates for deep brain stimulation surgery on the basis of
having intolerable motor complications of levodopa. No seri-
ous adverse events attributable to the study treatment or evi-
dence of immunotoxicity were reported in any of the patients
at the 6-month primary efficacy endpoint or in long-term, 36-
month follow-up. In addition, significant improvement in
motor function relative to baseline was reported in all cohorts
at 6 months, with corresponding reduction or stabilization of
effective levodopa dose, though these findings have not yet
appeared in a peer-reviewed journal. This early phase study
has been extended for long-term follow-up to further assess
the safety and tolerability of ProSavin treatment. In addition, a
preclinical study is reportedly underway to optimize the ef-
fective drug dose prior to testing in a randomized, placebo-
controlled human clinical trial [32].
AAV–Glial-derived Neurotrophic Factor
Gene therapy has also been utilized to deliver therapies aimed
at slowing disease progression and restoring neuronal function
(i.e., disease-modifying therapies). To date, these approaches
have utilized genes for neurotrophic factors to support the
function and survival of nigral dopaminergic neurons. In
particular, glial cell line-derived neurotrophic factor (GDNF)
is a neuron-type specific growth factor that has been studied
extensively for its potential application to PD [33]. Preclinical
studies in PD animal models have demonstrated that the direct
injection of GDNF into the striatum may be a safe and effec-
tive treatment aimed at reducing nigrostriatal dopaminergic
cell death, in addition to promoting dopamine axon sprouting
near the site of delivery [34–38]. These promising preclinical
observations, however, have not been replicated in human
clinical trials of direct GDNF injection [39–41], raising the
concern that delivery of GDNF may need to be more contin-
uous and better targeted in PD patients. This has led to the
investigation of viral vector-mediated delivery of GDNF genes
as an alternative to GDNF infusion. Several in vivo preclinical
studies have successfully evaluated GDNF gene delivery in
primate PD models using adenovirus-, lentivirus-, and AAV-
based vectors to transduce striatal cells [42–44]. Results from
these studies support a beneficial effect of GDNF expression
on nigrostriatal degeneration and related motor deficits.
The most extensively studied gene therapy of this type in
PD has been the gene for the GDNF family member,
Neurturin (NTN ). Intrastriatal injections of an AAV2 vector
encoding NTN in both MPTP primates and 6-OHDA rodent
models of PD have demonstrated the treatment to be safe and
effective [1]. These preclinical results led to a phase I, open-
label, clinical trial to test the safety and efficacy of bilateral
intraputaminal injection of NTN at 2 dose levels [45]. Twelve
PD patients were treated and showed a significant clinical
improvement (36 %) in off-medication motor UPDRS scores
at 1 year, though [18F]Fluorodopa PET imaging did not reveal
significant increases in dopaminergic nerve terminals after
12 months. Importantly, the treatment was safe and well-
tolerated, without serious adverse events. A subsequent ran-
domized, double-blind, sham surgery-controlled clinical trial
was conducted with 58 PD patients [46] in an effort to validate
the observed efficacy in the open-label trial. Unfortunately,
patients who received NTN did not show significant improve-
ment in the primary outcome measure of off-state motor
UPDRS scores at 12 months. However, in a post hoc analysis,
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a modest, but significant, improvement was observed in the 19
NTN-treated patients who continued blind to an 18-month
evaluation, suggesting that perhaps a longer observation peri-
od was needed to achieve a benefit. Postmortem analysis of 2
deceased patients demonstrated NTN expression in the puta-
men, but not in the substantia nigra, indicative of restricted
retrograde transport of the AAV vector.
Because of these factors, a second clinical trial was under-
taken to directly target the substantia nigra, inject a higher
dose to the putamen, and provide clinical follow-up for
3 years. A phase 1, open-label study in 6 PD patients demon-
strated the tolerability of treatment with CERE-120 delivered
to both the substantia nigra pars compacta and putamen,
and, in addition, there were no safety complications in
2 years of follow-up [47]. Based on these data, a phase
2b, double-blind, sham surgery-controlled trial was un-
dertaken to assess the efficacy of combined intraputaminal
and intranigral gene delivery of CERE-120 in PD patients.
Pre-publication press reports, however, indicate that this trial
has failed to demonstrate efficacy [48]. At 15 months, the
primary endpoint (off-state motor UPDRS scores) was not
improved, though there were significant improvements in
some secondary endpoints, including off time measured with
diaries. Importantly, the therapy was found to be safe and well
tolerated.
Other AAV2–GDNF gene therapies are also being studied
for PD, though enthusiasm for this approach may be dimin-
ished after the disappointing results for NTN. Currently, an
open-label dose-escalation study of AAV2–GDNF delivery in
advanced PD patients is enrolling patients to test the safety,
tolerability, and efficacy of 4 doses delivered bilaterally to the
putamen [49]. Patients will undergo clinical evaluations
regularly for 5 years post infusion, in addition to laboratory
studies, neuropsychological testing, and neuroimaging.
Recent studies have raised the possibility that GDNF may
not be effective on dopamine neurons with increased levels
of alpha-synuclein (SNCA) [50], suggesting that this thera-
peutic approach may be only effective for patients with rela-
tively mild PD, and perhaps providing an explanation for the
negative clinical trials to date.
Preclinical Gene Therapy Approaches to PD
AAV–TH–GCH
Analogous to the triple therapy approach currently used in
clinical trials utilizing a lentivirus vector, the development of
an AAV vector capable of delivering TH and GCH is also
being pursued. Recently, co-expression of TH and GCH
genes on a single AAV vector has been achieved and has been
tested in hemiparkinsonian rats and nonhuman primates [51].
A dose-dependent functional recovery associated with
enhanced levodopa production was observed following treat-
ment in unilateral 6-OHDA-lesioned rats. However, in a small
cohort of animals, loss of neurons in the globus pallidus
resulted from treatment. Further investigation revealed that
this cell loss was most likely associated with levodopa pro-
duction and its downstream effects on pallidal cells.
Moreover, it was determined that the dose of the TH–GCH1
vector can be adjusted to retain efficacy without causing
significant toxicity to globus pallidus or striatal neurons
[51]. However, when tested in primates, treatment with
AAV–TH–GCH did not result in any beneficial effect or
functional improvement during a 6-month assessment period.
Postmortem assessments of transgene expression demonstrat-
ed robust expression of GCH , but not TH , the cause of which
remains unknown. These issues must be resolved before the
AAV–TH–GCH vector can proceed to an early phase human
clinical trial. In addition, it remains uncertain if the use of
AAV provides an advantage over the current lentivirus-based
triple gene therapy approach.
SNCA Silencing
SNCA is a small, abundant protein that constitutes a major
component of the intracellular Lewy bodies and neurites
found in dopaminergic neurons in the substantia nigra of PD
patients [52]. Studies of familial forms of PD have identified
missense mutations in the gene encoding SNCA causing the
development of an abnormal protein with abnormal function
that in animals causes aggregation and parkinsonism. In addi-
tion to duplication and triplication of the locus containing the
gene [53, 54], polymorphisms in its promoter [55] and other
regions lead to increased expression [56]. The resulting over-
expression leads to aggregation of SNCA that may lead to
Lewy body formation and dopaminergic cell loss [57]. Gene
therapies that could down-regulate SNCA might therefore
have a role in the treatment of PD.
RNA interference (RNAi) is one method that could be used
to reduce SNCA gene expression. RNAi utilizes sequences of
RNA that are complimentary to specific regions of the mes-
senger RNA of interest, blocking protein translation. Viral
vectors can be used to deliver RNAi, and this method has
been successfully implemented in preclinical studies to reduce
the level of SNCA both in vitro [58, 59] and in vivo [60–62].
Nonetheless, several studies have suggested contradictory
conclusions; though reduced SNCA expression is associated
with a lower risk of developing PD [63], it is also associated
with worse motor and cognitive outcomes [64]. Similarly, a
preclinical study in a rat model reported motor deficits in
addition to degeneration of nigral dopaminergic neurons with
the knock-down of endogenous SNCA in the substantia
nigra [65, 66]. These results raise the possibility that the
relationship between SNCA expression and PD may be
more complicated than is currently appreciated. Indeed, it
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remains uncertain whether reducing SNCA would have a
beneficial effect in PD. An alternate approach might involve
inhibition of SNCA aggregation, and in vitro studies suggest
that gene therapy with a mutant SNCA gene that blocks
aggregation of wild-type PD-linked SNCAvariants [67] could
have a role in PD therapeutics.
Parkin
Nearly half of all familial PD cases and 15% of sporadic cases
with onset before the age of 45 years are associated with
mutations in the Parkin gene [68]. Parkin is a ligase that
polyubiquitinates proteins destined for degradation by the
proteasome [69]. The loss of Parkin function that results from
mutations in familial PD can lead to the accumulation of
potentially toxic substrate proteins in addition to dysfunctional
mitochondria [70]. Thus, another approach to gene therapy in
PD aims to restore normal Parkin function thereby protecting
nigral neurons. In unilaterally treated 6-OHDA rats, transduc-
tion of nigral cells with a lentiviral vector encoding Parkin
corrects motor asymmetry [71]. Likewise, in MPTP-treated
mice, gene therapy with AAV–Parkin protects dopaminergic
neurons [72]. Furthermore, in PD animal models in which
SNCA is overexpressed, gene transfer of Parkin significantly
reduces nigrostriatal degeneration resulting in behavioral im-
provements [73, 74]. Unfortunately, the single primate study
conducted to this point has not reported neuroprotective ef-
fects, but it was limited by sample size and incomplete trans-
duction [75]. Further preclinical work will be needed to de-
termine if Parkin gene therapymay have a role in the treatment
of PD.
Other Approaches
RNAi could also be utilized for blocking other gene mutations
associated with PD. For example, the PD-associated gene
mutations in leucine-rich repeat kinase 2 (LRRK2 ) could be
preferentially silenced over the wild-type LRRK2 . A recent
study reported effective targeting and subsequent silencing of
2 PD-related LRRK2 mutations in vitro using RNAi [76],
though whether this would reduce the risk of PD or affect
the progression of PD remains uncertain. Overall, as gene
therapy, including RNAi, can currently only target specific
brain regions, attempting to alter expression of genes such as
LRRK2 and SNCA may be limited as expression of these
genes is widespread. Nonetheless, targeting brain regions that
are primarily involved in PD pathology may have some utility.
Mitchondrial dysfunction has been implicated in the path-
ogenesis of PD, and improving mitochondrial function could
be a target of gene therapy. In vitro studies have suggested that
replenishing mitochondrial DNA using a novel protein-
mediated transfection technology (“ProtoFection”) may im-
prove neuron function and prevent cell death [77], and it has
been suggested that mitochondrial gene therapy could have a
role in sporadic PD treatment [78]. More specifically, replace-
ment of the impaired mitochondrial nicotinamide adenine
dinucleotide-quinone oxidoreductase (complex I) with a yeast
alternative nicotinamide adenine dinucleotide dehydrogenase,
Ndi1, has been shown to restore energetic balance and protect
nigrostriatal dopamine cells both in vitro [77] and in vivo [79].
Neuroinflammation has also been implicated in the patho-
genesis of PD, and gene therapy approaches to reducing
neuroinflammation are also being studied. For example, in
rat models of PD, both direct injection [80] and lentiviral
delivery [81] of a gene for a dominant-negative tumor necrosis
factor which selectively inhibits tumor necrosis factor, have
been shown to reduce neuroinflammation and attenuate pro-
gressive loss of nigral dopamine neurons.
Though these gene therapy approaches for the treatment of
PD remain theoretical and, in some cases, may either never
enter or be years from human clinical trials, they demonstrate
the wide variety of possible gene therapy targets for PD. As
more is learned about the pathogenesis of PD, it is likely that
new gene therapy targets will be identified.
Conclusion
Over the last 10 years, several gene therapy approaches for the
treatment of PD have entered human clinical trials. Some of
these trials have produced promising results, while others have
not, but the accumulating data suggest that gene therapy,
targeting multiple brain regions including the striatum, STN,
and substantia nigra, can be safe and well-tolerated in PD
patients. Significant challenges remain, including how to mod-
ulate gene expression and how to determine the optimal target,
dose, and patient population to study in future gene therapy
trials. Advances in these areas may require the development of
better animal models of PD, as well as improved methods for
assessing efficacy (e.g., biomarkers). Nonetheless, novel gene
therapy approaches to PD are currently being investigated in
preclinical models, and advances in the understanding of the
pathogenesis of PD and improvements in gene delivery
methods will likely drive further development of gene thera-
pies for PD.
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